Global Cell and Gene Therapy Manufacturing Services Market to 2028, Led by Catalent, Lonza, Merck KGaA, and Thermo Fisher Scientific
DUBLIN, July 26, 2023 /PRNewswire/ -- The "Cell and Gene Therapy Manufacturing Services Market" report has been added to ResearchAndMarkets.com's offering.
The global market for cell and gene therapy manufacturing services was estimated to be $4.9 billion in 2022 and is expected to increase to $11.8 billion by 2028, growing at a CAGR of 15.7%.
The cell and gene therapy manufacturing services market is segmented based on application, type, disease, end user, and region.
The scope of this study encompasses an investigation of cell and gene therapy manufacturing services. The report analyzes the manufacturing services based on therapy type, application, disease, and end user. The study determines the current market status in each segment, examines its impact on future markets, and presents growth forecasts over the next six years.
The recent report provides a detailed analysis of the market's drivers, challenges, and opportunities. The report also covers market projections to 2028 and market share for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides the ESG perspective, emerging technologies, and investment outlook.
The pharmaceutical industry is changing and moving away from a one-size-fits-all approach to a targeted and personalized approach, in which patients' own genetic information and immune systems are used to treat previously incurable diseases. Cell and gene therapies are different from the traditional biopharma products.
Cell and gene therapies (CGT) are a novel therapeutic modality for a range of chronic and age-related conditions. These provide a fundamental treatment option for disease conditions that do not have a cure or cannot be treated with conventional drugs. Initially, cell and gene therapies were highly explored for oncology. However, the research is expanding into other disease areas.
Demand for cell and gene therapies is high and there is a lot of R&D in this segment supported by huge investments and funding for CGTs. According to the Alliance for Regenerative Medicine 2022 report, CGT research raised nearly $19.9 billion in 2020, $22.7 billion in 2021 and $6.3 billion in the first half of 2022 (H1 2022) and overall investment of $12.6 billion. The number of clinical trials and regulatory approvals for cell and gene therapies will increase over the coming years. The FDA estimates that by 2025, it will approve 10-20 cell and gene therapy products per year, and it is forecasted that by 2030 there will be around 75 approved therapies.
Notably, even though awareness and demand are increasing, there is a lack of supply. This is mainly due to limited manufacturing capacity and complex supply chain. Hence, it is important that the organizations scale-up to meet the supply chain requirements. Also, due to stringent, expensive, and complex manufacturing processes, most of the small and medium sized pharma and biotech companies are engaging with contract development and manufacturing organizations (CDMO). This is a contributing factor to the growth of the CGT CDMO's.
Increasing investments, capacity expansions for clinical and commercial manufacturing, increasing prevalence of chronic diseases and focus on rare diseases, and increased healthcare expenditure drive the cell and gene therapy manufacturing services market. Accelerated approvals in recent years, coupled with technological advancements (development of off-the-shelf products, automations, application of advanced gene editing techniques like CRISPR), will lower the complexities involved around manufacturing CGTs and will attract many pharma and biotech companies to enter the market, thus contributing to the market in the forecast period.
The North American region has the highest share, followed by Europe. Extensive R&D activities take place in the region, there are major players present, plentiful funding, and increasing prevalence of chronic diseases. All these factors contribute to growth in the market. Based on application, the cancer segment has the highest share
Company Profiles
Catalent Inc.
Cell and Gene Therapy Catapult
Charles River Laboratories
Fujifilm Diosynth Biotechnologies
Lonza Group AG
Merck KGaA
Miltenyi Biotec
Nikon Cell Innovation Co. Ltd.
Takara Bio Inc.
Thermo Fisher Scientific
Wuxi Advanced Therapies
Report Includes
34 data tables and 18 additional tables
An overview of the global cell and gene therapy manufacturing services market
Analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Highlights of the market potential and quantification of market based on therapy type, application, disease, and end-user
A look into current technologies underlying the market as well as the effects new technologies will have on the market
Coverage of clinical trials pipeline, partnership between pharmaceutical companies, and Contract Development & Manufacturing Organization (CDMO)
Insights into investments from multiple stakeholders, and discussion on increasing focus on personalized medicine for rare and chronic conditions
Information on recent mergers, acquisitions, collaborations, agreements, product launches, and expansions in the market and a relevant patent analysis
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market Overview and Technology Background
Overview
Gene Addition or Augmentation
Gene Correction
Gene Silencing
Manufacturing
Supply Chain
Regulatory Landscape
U.S. (FDA)
Europe
Outsourcing of Manufacturing
Chapter 4 Market Dynamics
Factors Affecting the Market
Market Drivers
Increasing Investment and Funding for CGT Development
Capacity Expansions for Clinical and Commercial Manufacturing
Rising Prevalence of Chronic Diseases and Focus on Rare Diseases
Increasing Strategic Collaborations and Acquisitions
Market Restraints
Complex Manufacturing and Supply Chain
Lack of Skilled Workforce
Regulatory Hurdles
Market Opportunities
Chapter 5 Emerging Technologies
Introduction
Emerging Technologies
Automation
Digitalization
Single-Use Technologies
Emerging Manufacturing Models
Chapter 6 Market Breakdown by Type
Overview
Cell Therapy
Gene Therapy
Cell Therapy Types
Autologous Cell Therapy
Allogeneic Cell Therapy
Cell and Gene Therapy Types Based on Vector Type
Viral Vectors
Nonviral Vectors
Chapter 7 Market Breakdown by Application
Overview
Clinical Manufacturing
Commercial Scale Manufacturing
Chapter 8 Market Breakdown by Disease
Overview
Cancer
Rare Diseases
Other Diseases
Chapter 9 Market Breakdown by End User
Overview
Pharmaceutical and Biotechnology Companies
Academic and Research Institutes
Others
Chapter 10 Market Breakdown by Region
Chapter 11 Sustainability: An ESG Perspective
Chapter 12 M&A, Funding Outlook and Competitive Landscape
Chapter 13 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/hg66o5
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-cell-and-gene-therapy-manufacturing-services-market-to-2028-led-by-catalent-lonza-merck-kgaa-and-thermo-fisher-scientific-301886318.html
SOURCE Research and Markets
